中国药理学通报
中國藥理學通報
중국약이학통보
CHINESE PHARMACOLOGICAL BULLETIN
2014年
5期
604-607
,共4页
戴杏%贾晓益%吴育晶%魏伟
戴杏%賈曉益%吳育晶%魏偉
대행%가효익%오육정%위위
B细胞受体信号通路%恶性淋巴瘤%Syk%Btk%PI3K%靶向抑制剂
B細胞受體信號通路%噁性淋巴瘤%Syk%Btk%PI3K%靶嚮抑製劑
B세포수체신호통로%악성림파류%Syk%Btk%PI3K%파향억제제
BCR signaling%lymphoid malignancies%Syk%Btk%PI3K%targeted inhibitors
淋巴瘤是来源于成熟淋巴细胞的恶性肿瘤,B细胞受体( B cell receptor,BCR)信号通路在B细胞的发育和维持中起重要作用。恶性B细胞的生长和存活由BCR及其信号通路介导。目前,已相继研发了针对通路的各种靶酶如Syk、Btk及PI3K的抑制剂。该文对BCR信号通路及其靶向抑制剂在恶性淋巴瘤中作用的研究进展做一综述。
淋巴瘤是來源于成熟淋巴細胞的噁性腫瘤,B細胞受體( B cell receptor,BCR)信號通路在B細胞的髮育和維持中起重要作用。噁性B細胞的生長和存活由BCR及其信號通路介導。目前,已相繼研髮瞭針對通路的各種靶酶如Syk、Btk及PI3K的抑製劑。該文對BCR信號通路及其靶嚮抑製劑在噁性淋巴瘤中作用的研究進展做一綜述。
림파류시래원우성숙림파세포적악성종류,B세포수체( B cell receptor,BCR)신호통로재B세포적발육화유지중기중요작용。악성B세포적생장화존활유BCR급기신호통로개도。목전,이상계연발료침대통로적각충파매여Syk、Btk급PI3K적억제제。해문대BCR신호통로급기파향억제제재악성림파류중작용적연구진전주일종술。
Lymphoma is a malignancy of mature lymphocytes. Signalling through the B cell receptor ( BCR ) is central to the development and maintenance of B cells. In light of the numer-ous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival. Compounds that inhibit various components of this pathway, in-cluding spleen tyrosine kinase(Syk), Bruton’s tyrosine kinase (Btk), and phosphoinositol-3 kinase(PI3K), have been devel-oped. In this paper,the B-cell receptor signaling and its targeted inhibitors of lymphoid malignancies are reviewed.
